Search

everythinglearnresearchcommunity

for

Search:↓

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Lack of KSR1 stops certain skin tumors in mice.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Upadacitinib effectively treated severe hair loss in a child.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Upadacitinib may effectively treat resistant lichen planopilaris.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

RIPK1 inhibitors might help prevent alopecia areata.

AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.

The inhibitor affects androgen metabolism but not ovarian function.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

Blocking DKK1 with siRNA can improve hair growth.

Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.

Ruxolitinib helped a patient with alopecia areata regrow hair.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Ruxolitinib cream may help treat severe hair loss in children.

Topical Ruxolitinib may safely treat severe hair loss.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Baricitinib for alopecia areata may rarely cause eye issues like keratitis.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.